Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.45 |
| ▸ | HTR1A | P08908 | 15/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5236500 | 0.91 | SLC6A4 (0.48) | SLC6A4HTR1ACYP3A4CYP2C8DRD2 | |
| SCHEMBL5238549 | 0.89 | MPO (0.52) | SLC6A4HTR1AMPO | |
| SCHEMBL6894817 | 0.88 | HTR1A (0.51) | SLC6A4HTR1ACYP3A4CYP2C8DRD2 | |
| SCHEMBL5234175 | 0.85 | HTR1A (0.44) | SLC6A4HTR1ADRD2 | |
| SCHEMBL5233844 | 0.80 | HTR1A (0.48) | SLC6A4HTR1AMPO | |
| SCHEMBL5232383 | 0.79 | HTR1A (0.52) | SLC6A4HTR1ACYP3A4CYP2C8DRD2 | |
| SCHEMBL5236133 | 0.77 | HTR1A (0.50) | SLC6A4HTR1ACYP3A4CYP2C8DRD2 | |
| SCHEMBL5236576 | 0.77 | MPO (0.52) | SLC6A4HTR1AMPO | |
| SCHEMBL5234085 | 0.74 | HTR1A (0.50) | SLC6A4HTR1AMPO | |
| SCHEMBL5232373 | 0.74 | HTR1A (0.49) | SLC6A4HTR1ACYP3A4CYP2C8DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138222-A1 | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines | WYETH | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138222-A1 | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines | HTR5A, TPH1, DBH | SLC6A4 42/4885HTR1A 13/4885CYP3A4 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.